Clinical value of adjuvant therapy for esophageal cancer after radical resection

Abstract

Abstract:Surgery is the standard therapy for esophageal cancer, however, the postoperative overall survival rate is still disappointed. Local recurrence and regional lymph node metastasis are the main failure models. The optimal therapeutic modality for these patients with radical resection remains unclear. Some researches indicate that patients with stage Ⅲ, N1 can benefit from postoperative radiotherapy, which can improve the diseasefree survival and overall survival ratio. The irradiation field depends on the site of tumor removal (tumor bed) during surgery. The cisplatin plus 5fluorouracil chemotherapy regimen seems as the preferred for postoperative adjuvant chemotherapy, the mainly adverse reactions are digestive tract reactions and myelosuppression. The clinical value of postoperative adjuvant chemoradiotherapy still needs more clinical trials to support.

Key words:Esophageal neoplasms,Esophagectomy,Neoadjuvant therapy

Fang Weisheng, Lai Peibao, Wang Xiaoyan, et al. Clinical value of adjuvant therapy for esophageal cancer after radical resection[J]. Journal of International Oncology, 2014, 41(1): 34-37.

References

［1］ Krasna MJ. Multimodality therapy for esophageal cancer ［J］. Oncology, 2010, 24(12):11341138. ［2］ Shahbaz Sarwar CM, Luketich JD, Landreneau RJ, et al. Esophageal Cancer: An update ［J］. Int J Surg, 2010, 8 (6):417422. ［3］ Jingu K, Matsushita H, Takeda K, et al. Longterm results of radiotherapy combined with nedaplatin and 5fluorouracil for postoperative locoregional recurrent esophageal cancer: update on a phase Ⅱ study［J］. BMC Cancer, 2012, 12:542. ［4］ Calvo FA, Sole CV, Obregón R, et al. Postchemoradiation resected locally advanced esophageal and gastroesophageal junction carcinoma: longterm outcome with or without intraoperative radiotherapy［J］. Ann Surg Oncol, 2013, 20(6):19621969. ［5］ Rodriguez CP, Adelstein DJ, Rice TW, et al. A phase Ⅱ study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer ［J］. J Thorac Onocl, 2010, 5(2):229235. ［6］ Schreiber D, Rineer J, Vongtama D, et al. Impact of postoperative radiation after esophagectomy for esophageal cancer［J］. J Thorac Oncol, 2010, 5(2):244250. ［7］ Chen J, Zhu J, Pan J, et al. Postoperative radiotherapy improved survival of poor prognostic squamous cell carcinoma esophagus［J］. Ann Thorac Surg, 2010, 90(2):435442. ［8］ Akutsu Y, Matsubara H. The significance of lymph node status as a prognostic factor for esophageal cancer［J］. Surg Today, 2011, 41(9):11901195. ［9］ Chen J, Pan J, Zheng X, et al. Number and location of positive nodes, postoperative radiotherapy, and survival after esophagectomy with threefield lymph node dissection for thoracic esophageal squamous cell carcinoma. ［J］. Int J Radiat Oncol Biol Phys, 2010, 82(1):475482. ［10］ Mariette C, Piessen G, Briez N, et al. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent ［J］. Ann Surg, 2008, 247(2):365371. ［11］ Greenstein AJ, Litle VR, Swanson SJ, et al. Prognostic significance of the number of lymph node metastases in esophageal cancer ［J］. J Am Coll Surg, 2008, 206(2):239246. ［12］ Cai WJ, Xin PL. Pattern of relapse in surgical treated patients with thoracic esophageal squamous cell carcinoma and its possible impact on target delineation for postoperative radiotherapy ［J］. Radiother Oncol, 2010, 96(1):104107. ［13］刘俊, 吕长兴, 王家明, 等. 104例胸段食管癌左胸路径术后局部复发规律及放疗靶区范围探讨［J］. 中华放射肿瘤学杂志, 2013, 22(2):111114. ［14］陈俊强, 潘建基, 陈明强, 等. 胸段食管鳞癌淋巴结转移数和区域与术后放疗价值的临床研究［J］. 中华放射肿瘤学杂志, 2010, 19(2):105109. ［15］章文成, 王奇峰, 肖泽芬, 等. 胸段食管鳞癌根治术后失败模式对放疗野设计的指导作用［J］. 中华放射肿瘤学杂志, 2012, 21(1):3841. ［16］ Tachimori Y, Nagai Y, Kanamori N, et al. Pattern of lymph node metastases of esophageal squamous cell carcinoma based on the anatomical lymphatic drainage system ［J］. Dis Esophagus, 2011, 24(1):3338. ［17］ Fenkell L, Kaminsky I, Breen S, et al. Dosimetric comparison of IMRT vs. 3D conformal radiotherapy in the treatment of cancer of the cervical esophagus［J］. Radiother Oncol, 2008, 89(3):287291. ［18］ Asakura H, Hashimoto T, Zenda S, et al. Analysis of dosevolume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer ［J］. Radiother Oncol, 2010, 95(2):240244. ［19］ Wang J, Wei C, Tucker SL, et al. Predictors of Postoperative Complications After Trimodality Therapy for Esophageal Cancer［J］. Int J Radiat Oncol Biol Phys, 2013, 86(5):885891. ［20］ Zhang J, Chen HQ, Zhang YW, et al. Adjuvant chemotherapy in oesophageal cancer: a metaanalysis and experience from the Shanghai Cancer Hospital［J］. J Int Med Res, 2008, 36(5):875882. ［21］ Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated metaanalysis［J］. Lancet Oncol, 2011, 12(7):681692. ［22］ Kranzfelder M, Schuster T, Geinitz H, et al. Metaanalysis of neoadjuvant treatment modalities and definitive nonsurgical therapy for oesophageal squamous cell cancer［J］. Br J Surg, 2011, 98(6):768783. ［23］王肇炎. 食管癌药物治疗的前景困难及对策［J］. 中华肿瘤杂志, 2011, 33(2):157159. ［24］ Yamamoto Y, Yamai H, Seike J, et al. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, Fluorouracil, and cisplatin［J］. Ann Surg Oncol, 2012, 19(3):757765. ［25］ Neuner G, Patel A, Suntharalingam M. Chemoradiotherapy for Esophageal Cancer［J］. Gastrointest Cancer Res, 2009, 3(2):5765. ［26］ Adelstein DJ, Rice TW, Rybicki LA, et al. Mature results from a phase Ⅱ trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction［J］. J Thorac Oncol, 2009, 4(10):12641269. ［27］ Wu S, Deng X, Zhang P, et al. Phase Ⅱ study of postoperative chemoradiotherapy for esophageal carcinoma［J］. J Clin Oncol, 2009, 27 Suppl 15:e15606 ［28］ Yeh HL, Hsu CP, Lin JC, et al. A retrospective study of postoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma［J］. Form J Surg, 2012, 45:172177.

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[3]	Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209.
[4]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[5]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei.Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients[J]. Journal of International Oncology, 2024, 51(1): 37-42.
[6]	Shandong Medical Association Multidisciplinary Joint Committee on Lung Cancer.Shandong Provincial Medical Association multidisciplinary standardized diagnosis and treatment guidelines for esophageal carcinoma （2023 Edition）[J]. Journal of International Oncology, 2023, 50(7): 385-397.
[7]	Xu Fang, Zhu Wentian.Progress in adjuvant therapy of hepatocellular carcinoma complicated with microvascular invasion[J]. Journal of International Oncology, 2023, 50(5): 304-309.
[8]	Ji Shiyu, Zhang Mingxin, Xie Huahong, Bai Yuan, Wang Tong.Observation on the efficacy of different stents in the treatment of patients with advanced esophageal cancer[J]. Journal of International Oncology, 2023, 50(2): 76-81.
[9]	Gong Heyi, Yi Yan, Zhang Jian, Li Baosheng.Management strategies for locally advanced operable esophageal carcinoma achieving clinical complete response after neoadjuvant chemoradiotherapy[J]. Journal of International Oncology, 2023, 50(12): 745-750.
[10]	Wu Puyuan, Qi Liang, Wang Tao, Shi Minke, Sun Yuwei, Wang Lifeng, Liu Baorui, Yan Jing, Ren Wei.Efficacy of postoperative radiotherapy based on modified clinical target volume according to high-frequency recurrence regions in patients with esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2022, 49(8): 464-472.
[11]	Xia Lingling, Chen Yongshun, Li Bin, Ning Tingting, Zhang Caiyutian.Comparison of safety and efficacy between chemoradiotherapy and chemotherapy after R0 resection in pN₊esophageal squamous cell carcinoma patients[J]. Journal of International Oncology, 2022, 49(6): 334-339.
[12]	Cai Gangxiang, Li Jing, Xu Bin.Advances in neoadjuvant immunotherapy for lung cancer[J]. Journal of International Oncology, 2022, 49(6): 366-370.
[13]	Ye Qian, Ling Zhi, Liu Shenxiang, Lu Guotao, Yin Xudong.Effects of sarcopenia on the clinical efficacy and prognosis of radical radiotherapy in elderly patients with esophageal cancer[J]. Journal of International Oncology, 2022, 49(4): 199-205.
[14]	Zhou Jianfeng, Wang Tiejun.Targeted therapy and immunotherapy of esophageal cancer[J]. Journal of International Oncology, 2022, 49(4): 237-242.
[15]	Liu Jia, Ge Xiaolin, Di Xiaoke, Shi Yujing, Zeng Yuting.Efficacy analysis of Xiyanping injection on prevention of radioactive esophagitis[J]. Journal of International Oncology, 2022, 49(3): 146-150.